Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Score) was the recipient of a giant lower briefly curiosity in September. As of September fifteenth, there was brief curiosity totalling 6,170,000 shares, a lower of 9.3% from the August thirty first whole of 6,800,000 shares. Roughly 17.5% of the corporate’s inventory are bought brief. Primarily based on a mean day by day quantity of 686,900 shares, the short-interest ratio is presently 9.0 days.
Insiders Place Their Bets
In different information, Director Julie Papanek Grant bought 87,647 shares of the agency’s inventory in a transaction dated Tuesday, September thirteenth. The inventory was bought at a mean value of $24.40, for a complete worth of $2,138,586.80. Following the completion of the transaction, the director now owns 9,575,998 shares within the firm, valued at roughly $233,654,351.20. The sale was disclosed in a submitting with the Securities & Alternate Fee, which is out there by this hyperlink. In different information, Director Julie Papanek Grant bought 87,647 shares of the agency’s inventory in a transaction dated Tuesday, September thirteenth. The inventory was bought at a mean value of $24.40, for a complete worth of $2,138,586.80. Following the completion of the transaction, the director now owns 9,575,998 shares within the firm, valued at roughly $233,654,351.20. The sale was disclosed in a submitting with the Securities & Alternate Fee, which is out there by this hyperlink. Additionally, main shareholder Xi L.P. Canaan bought 148,670 shares of the agency’s inventory in a transaction dated Tuesday, September twentieth. The shares had been bought at a mean value of $19.51, for a complete worth of $2,900,551.70. Following the completion of the transaction, the insider now owns 9,077,904 shares of the corporate’s inventory, valued at roughly $177,109,907.04. The disclosure for this sale will be discovered right here. Within the final 90 days, insiders bought 1,259,087 shares of firm inventory price $25,378,315. Company insiders personal 8.70% of the corporate’s inventory.
Institutional Buyers Weigh In On Day One Biopharmaceuticals
Plenty of hedge funds and different institutional buyers have not too long ago made adjustments to their positions within the enterprise. ACG Wealth acquired a brand new stake in shares of Day One Biopharmaceuticals within the second quarter valued at roughly $32,000. TCI Wealth Advisors Inc. purchased a brand new place in Day One Biopharmaceuticals within the second quarter valued at roughly $35,000. Quantbot Applied sciences LP purchased a brand new place in Day One Biopharmaceuticals within the second quarter valued at roughly $51,000. Amalgamated Financial institution purchased a brand new place in Day One Biopharmaceuticals within the first quarter valued at roughly $30,000. Lastly, California State Academics Retirement System elevated its stake in Day One Biopharmaceuticals by 58.6% within the first quarter. California State Academics Retirement System now owns 9,687 shares of the corporate’s inventory valued at $96,000 after buying a further 3,581 shares over the past quarter. 95.40% of the inventory is presently owned by institutional buyers and hedge funds.
Day One Biopharmaceuticals Buying and selling Up 2.1 %
DAWN inventory traded up $0.41 throughout mid-day buying and selling on Friday, hitting $20.03. 887,058 shares of the corporate had been exchanged, in comparison with its common quantity of 855,467. The enterprise has a 50 day easy shifting common of $21.98 and a 200-day easy shifting common of $15.36. Day One Biopharmaceuticals has a 1-year low of $5.44 and a 1-year excessive of $28.35.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Score) final issued its quarterly earnings knowledge on Thursday, August 4th. The corporate reported ($0.60) earnings per share (EPS) for the quarter, lacking the consensus estimate of ($0.49) by ($0.11). As a bunch, analysts predict that Day One Biopharmaceuticals will submit -2.18 earnings per share for the present 12 months.
Wall Road Analyst Weigh In
A number of equities analysis analysts not too long ago issued studies on DAWN shares. Piper Sandler raised their goal value on shares of Day One Biopharmaceuticals from $35.00 to $40.00 and gave the corporate an “obese” ranking in a analysis be aware on Monday, June twentieth. Wedbush raised their goal value on shares of Day One Biopharmaceuticals from $32.00 to $35.00 and gave the corporate an “outperform” ranking in a analysis be aware on Monday, June thirteenth.
About Day One Biopharmaceuticals
(Get Score)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical firm, develops and commercializes focused therapies for sufferers with genetically outlined cancers. Its lead product candidate is DAY101, an oral brain-penetrant sort II pan-rapidly accelerated fibrosarcoma kinase inhibitor that’s in Part II scientific trial for pediatric sufferers with relapsed/progressive low-grade glioma.
Learn Extra
This instantaneous information alert was generated by narrative science expertise and monetary knowledge from MarketBeat to be able to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.
Earlier than you think about Day One Biopharmaceuticals, you may wish to hear this.
MarketBeat retains monitor of Wall Road’s top-rated and greatest performing analysis analysts and the shares they advocate to their shoppers each day. MarketBeat has recognized the 5 shares that high analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Day One Biopharmaceuticals wasn’t on the listing.
Whereas Day One Biopharmaceuticals presently has a “Purchase” ranking amongst analysts, top-rated analysts imagine these 5 shares are higher buys.
View The 5 Shares Right here
